Responding to emergence of drug-resistant tuberculosis

Jan 27 2012

This post in the Center for Strategic and International Studies' "Smart Global Health" blog examines drug-resistant tuberculosis (TB), stating, "[S]ince the recent outbreak of the so-called totally drug-resistant tuberculosis (TDR-TB) in India, TB has a new face." The blog details what TDR-TB is, recaps how resistant strains of TB develop and suggests several ways in which the global health community should respond (Kramer, 1/25).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Disease/Infection News | Healthcare News

Tags: , , , ,

Comments (0)

Suggested Reading

Minority genetic variation in tuberculosis offers new insights for improving outbreak tracking
Self-destructing vaccine offers safer TB protection in monkeys
WHO reports alarming rise in tuberculosis cases in 2023
Quabodepistat combo shows promise for safer, faster tuberculosis treatment
UMass Amherst researcher receives $2.2 million grant to study tuberculosis response
TB pathogen's surprising growth mechanism challenges bacterial biology
Rutgers study sheds light on how bedaquiline fights drug-resistant tuberculosis
Brazil's cash transfer program cuts tuberculosis cases and deaths among vulnerable populations

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
WHO grants prequalification to molecular diagnostic test for tuberculosis